• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

2.440 -0.030 (-1.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗
March 10, 2026
Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million. 
Via Stocktwits
Topics Intellectual Property
Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q4 2025 Results Amid Strategic Expansion ↗
March 10, 2026
Via Chartmill
News headline image
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 10, 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
March 03, 2026
From Corstasis Therapeutics Inc.
Via Business Wire
News headline image
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
March 03, 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
 
Via Benzinga
News headline image
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
February 24, 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in The 2026 Citizens Life Sciences Conference
February 18, 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
February 17, 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 11, 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 11, 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
December 19, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 09, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug ↗
November 25, 2025
Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage. 
Via Stocktwits
News headline image
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
November 21, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
November 19, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
November 18, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
November 10, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 06, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
November 06, 2025
 
Via Benzinga
News headline image
Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗
November 06, 2025
Esperion's Q3 2025 shows strong revenue growth beating estimates, but a deeper loss led to a sharp stock sell-off. The company secured key patents and targets profitability in 2026. 
Via Chartmill
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
November 06, 2025
 
Via Benzinga
News headline image
Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
November 06, 2025
 
Via Benzinga
News headline image
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
November 04, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Jefferies Global Healthcare Conference - London
November 03, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
October 28, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
October 27, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Third Quarter 2025 Financial Results on November 6
October 23, 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap